SCHEMBL791195

SCHEMBL791195

NCCCCN1CCN(c2cccc3[nH]ccc23)CC1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.61
DRD3 P35462 3/20 0.61
DRD4 P21917 1/20 0.61
GAA P10253 5/20 0.57
MAPT P10636 3/20 0.56
ADRB1 P08588 1/20 0.56
HTR6 P50406 1/20 0.56
ADRA1A P35348 1/20 0.55
MEN1 O00255 1/20 0.50
GFER P55789 1/20 0.50
KMT2A Q03164 1/20 0.50
FAAH O00519 1/20 0.48
CNR1 P21554 1/20 0.48
SLC6A4 P31645 1/20 0.47
GOT1 P17174 1/20 0.46
RECQL P46063 1/20 0.46
HTR1A P08908 1/20 0.45
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7534110 0.91 DRD2 (0.65) DRD2DRD3DRD4GAAMAPT
SCHEMBL17817484 0.86 DRD2 (0.60) DRD2DRD3DRD4GAAMAPT
SCHEMBL29046800 0.85 DRD2 (0.66) DRD2DRD3DRD4GAAMAPT
SCHEMBL3208122 0.84 DRD2 (0.57) DRD2DRD3DRD4GAAMAPT
SCHEMBL7732059 0.82 DRD2 (0.69) DRD2DRD3DRD4GAAMAPT
SCHEMBL5113532 0.82 DRD2 (0.65) DRD2DRD3DRD4GAAMAPT
SCHEMBL2161623 0.82 DRD2 (0.58) DRD2DRD3DRD4GAAMAPT
SCHEMBL7093713 0.81 DRD2 (0.60) DRD2DRD3DRD4GAAMAPT
SCHEMBL15064732 0.81 HTR1A (0.63) DRD2DRD3DRD4GAAADRA1A
SCHEMBL7528034 0.81 DRD2 (0.57) DRD2DRD3DRD4GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029682-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME PIERRE FABRE MEDICAMENT (FR) 2010-02-04 US claimed
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2014-11-13 US disclosed
US-8822517-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z O.O. (PL) 2014-09-02 US disclosed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP disclosed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US disclosed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO disclosed
US-20100029682-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME PIERRE FABRE MEDICAMENT (FR) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029682-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME DRD3, CHRNA3, CHRM3 DRD2 13/4885DRD3 1/4885DRD4 26/4885
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS DRD2 3216/4885DRD3 3561/4885DRD4 3761/4885
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS DRD2 3216/4885DRD3 3561/4885DRD4 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.